Last reviewed · How we verify
Uritos®
Uritos is a uricosuric agent that increases urinary excretion of uric acid by inhibiting renal urate reabsorption.
Uritos is a uricosuric agent that increases urinary excretion of uric acid by inhibiting renal urate reabsorption. Used for Hyperuricemia and gout prophylaxis.
At a glance
| Generic name | Uritos® |
|---|---|
| Also known as | Imidafenacin |
| Sponsor | R-Pharm |
| Drug class | Uricosuric agent / URAT1 inhibitor |
| Target | URAT1 (urate transporter 1) |
| Modality | Small molecule |
| Therapeutic area | Rheumatology / Metabolic Disorders |
| Phase | Phase 3 |
Mechanism of action
Uritos works by blocking urate transporters in the kidney, primarily URAT1, which normally reabsorb filtered uric acid back into the bloodstream. By preventing this reabsorption, the drug increases the amount of uric acid eliminated in the urine, thereby lowering serum uric acid levels. This mechanism is distinct from xanthine oxidase inhibitors and is used to treat hyperuricemia and gout.
Approved indications
- Hyperuricemia and gout prophylaxis
Common side effects
- Headache
- Diarrhea
- Nausea
- Gout flare
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Uritos® CI brief — competitive landscape report
- Uritos® updates RSS · CI watch RSS
- R-Pharm portfolio CI